RecruitingPhase 3NCT06615050

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation

Sponsor

Incyte Corporation

Enrollment

572 participants

Start Date

Apr 2, 2025

Study Type

INTERVENTIONAL

Conditions

Graft-Versus-Host-Disease (GVHD)

Summary

The purpose of this study is to assess Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Cyclophosphamide, a drug called Methotrexate (MTX), and others for people with graft-versus-host-disease (gvhd). The study is currently recruiting participants at 30 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTacrolimus (Tac)

Tablet or intravenously (IV)

DRUGMethotrexate (MTX)

Intravenously (IV)

DRUGRuxolitinib (Rux)

Tablet

DRUGCyclophosphamide

Intravenously (IV)

DRUGMycophenolate mofetil (MMF)

Tablet or intravenously (IV)

Locations(30)

Stanford Cancer Center

Palo Alto, California, United States

University of California San Francisco

San Francisco, California, United States

University of Miami

Miami, Florida, United States

Moffitt Cancer Center

Tampa, Florida, United States

Blood and Marrow Transplant Group of Georgia

Atlanta, Georgia, United States

Indiana University Cancer Center

Indianapolis, Indiana, United States

University of Kansas Hospital Authority

Kansas City, Kansas, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Dana Farber Cancer Institute

Boston, Massachusetts, United States

University of Michigan

Ann Arbor, Michigan, United States

Karmanos Cancer Institute

Detroit, Michigan, United States

Henry Ford Hospital

Detroit, Michigan, United States

Washington University

St Louis, Missouri, United States

Mount Sinai Hospital

New York, New York, United States

Memorial Sloan Kettering

New York, New York, United States

University of North Carolina At Chapel Hill

Chapel Hill, North Carolina, United States

Levine Cancer Institute

Charlotte, North Carolina, United States

Duke University Medical Center

Durham, North Carolina, United States

Cleveland Clinic

Cleveland, Ohio, United States

Ohio State University

Columbus, Ohio, United States

Oregon Health & Science University

Portland, Oregon, United States

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Medical University of South Carolina

Charleston, South Carolina, United States

Sarah Cannon

Nashville, Tennessee, United States

Vanderbilt Medical Center

Nashville, Tennessee, United States

Baylor College of Medicine

Houston, Texas, United States

Virginia Commonwealth University, North Hospital

Richmond, Virginia, United States

Fred Hutchinson Cancer Research Center

Seattle, Washington, United States

University of Wisconsin

Madison, Wisconsin, United States

Medical College of Wisconsin

Milwaukee, Wisconsin, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06615050

Related Trials

Low-Dose ATG/PTCy Plus Ivarmacitinib for aGVHD Prevention in Haplo-PBSCT From Parous Female Donors

NCT075707451 location

Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention

NCT069265951 location

Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation

NCT067991951 location

Dapagliflozin in Allo-HCT for aGVHD

NCT066267371 location